Skip to content
sellModerate cluster of 2

Brad Hively sold $5.7M of STLN

director at Oncology Institute, Inc.. 1,976,137 shares at an average of $2.87, traded Jun 3, 2025, filed Jun 5, 2025.

Warning score
53
Value
$5.7M
1,976,137 shares
Holdings after
603,501
-77% from before
From 52-week low
+2324%
low $0.13, close $3.20
From 52-week high
-3%
high $3.31, as of Jun 3, 2025

Score components

  • Role
    Director
    +15
  • Trade size
    $5.7M at market
    +25
  • Share of holdings sold
    Sold 77% of holdings
    +20
  • Cluster
    2 insiders selling within 14 days
    +8
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m -9.7%, 3m +16.8%, 6m +15.8%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

STLNOct 12, 2026 · close 6.92
Since filing Jun 5, 2025: +148.0%SPY +33.4% · excess +114.6%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0000935836-25-000416, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Jun 3, 2025MOption exercise
Common Stock
+684,528$0.85$582k1,396,561Jun 5, 2025
Jun 3, 2025MOption exercise
Common Stock
+105,320$0.48$51k1,501,881Jun 5, 2025
Jun 3, 2025MOption exercise
Common Stock
+131,297$1.87$246k1,633,178Jun 5, 2025
Jun 3, 2025MOption exercise
Common Stock
+946,460$0.85$804k2,579,638Jun 5, 2025
Jun 3, 2025SOpen-market sale
Common Stock
-1,867,605$2.87$5.4M712,033Jun 5, 2025
Jun 3, 2025SOpen-market sale
Common Stock
-108,532$2.87$312k603,501Jun 5, 2025
Jun 3, 2025MOption exercise
Non-Qualified Stock Option (right to buy)derivative
+684,528$0.00$00Jun 5, 2025
Jun 3, 2025MOption exercise
Non-Qualified Stock Option (right to buy)derivative
+105,320$0.00$00Jun 5, 2025
Jun 3, 2025MOption exercise
Non-Qualified Stock Option (right to buy)derivative
+131,297$0.00$00Jun 5, 2025
Jun 3, 2025MOption exercise
Non-Qualified Stock Option (right to buy)derivative
+946,460$0.00$00Jun 5, 2025

Related signals

Other insiders at Oncology Institute, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
30Weak
STLNsell10b5-1
Oncology Institute, Inc.
Brad Hively
director
$1.9M
298,853 shares
-42%
26Weak
STLNbuy
Oncology Institute, Inc.
Jorey Chernett
owner
$78k
12,000 shares
+0%
27Weak
STLNbuy
Oncology Institute, Inc.
Jorey Chernett
owner
$95k
18,000 shares
+0%
0Weak
STLNsell10b5-1
Oncology Institute, Inc.
Yale Podnos
Chief Medical Officer
$150k
23,452 shares
-8%
26Weak
STLNbuy
Oncology Institute, Inc.
Jorey Chernett
owner
$88k
15,000 shares
+0%
16Weak
STLNbuy
Oncology Institute, Inc.
Jorey Chernett
owner
$90k
18,000 shares
+0%
6Weak
STLNsell10b5-1
Oncology Institute, Inc.
Yale Podnos
Chief Medical Officer
$126k
23,451 shares
-8%
14Weak
STLNbuy
Oncology Institute, Inc.
Jorey Chernett
owner
$57k
12,000 shares
+0%
18Weak
STLNbuy
Oncology Institute, Inc.
Jorey Chernett
owner
$157k
38,500 shares
+0%
17Weak
STLNbuy
Oncology Institute, Inc.
Jorey Chernett
owner
$123k
30,000 shares
+0%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Brad Hively sold $5.7M of STLN | InsiderTell